Preventive Pharmacological Treatment of Migraine: International Headache Society (IHS) Global Practice Recommendations

The article presents an adapted translation of the practice recommendations for the preventive treatment of migraine, released in late 2024 by the International Headache Society (IHS). The document contains 16 of the most important practical questions on migraine prevention, the answers to which are obtained from clinical guidelines from different countries, meta-analyses and randomized clinical trials (RCTs).The main objective of these practice recommendations for migraine prevention is to optimize the use of drugs for effective control of frequent and chronic migraine and to improve the quality of medical care for the greatest number of patients in countries with different levels of economic development. In the Russian Federation (RF), both targeted prophylactic drugs (anti-CGRP monoclonal antibodies, gepants), botulinum toxin type A and most classical oral medications are available. Thus, in our country it is possible to offer preventive treatment of migraine of any level, including the optimal one. In the comments to this article, the authors of the Russian version sought to adapt the answers to the most important questions to clinical practice in the Russian Federation.